| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4-Aminophenylboronic acid pinacol ester does not have a specific biological target. It is a chemical reagent and building block used in organic synthesis and drug discovery. The boronic ester moiety is widely used in Suzuki-Miyaura cross-coupling reactions to construct biaryl structures found in many pharmaceuticals. The compound itself is not pharmacologically active but serves as a precursor for synthesizing bioactive molecules.
|
|---|---|
| ln Vitro |
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline is a structural unit that is heterocyclic. It has been utilized to create roscovitine derivatives, which are CDKs (cyclin-dependent kinases) and casein Dual inhibitor of kinase 1 (CK1), as well as 3-aminoindazole-based multi-target receptor tyrosine kinase (RTK) inhibitors with anticancer action.
4-Aminophenylboronic acid pinacol ester is a chemical reagent and does not possess intrinsic in vitro biological activity. Its value lies in its utility for synthesizing biologically active molecules, including pharmaceuticals and agrochemicals. The compound is used in Suzuki-Miyaura cross-coupling reactions to construct complex biaryl structures. It is also used in fluorometric detection of mercury(II). It is not directly assayed for biological effects. |
| ln Vivo |
This compound is not a pharmacologically active agent and does not have intrinsic in vivo activity. Its applications in vivo are limited to its use as a synthetic intermediate for producing drug candidates that are subsequently evaluated in animal models. The compound is not administered to animals as a test compound.
|
| Enzyme Assay |
4-Aminophenylboronic acid pinacol ester is not typically used in cell-free enzyme/receptor binding assays. Its role in drug discovery is as a synthetic building block for Suzuki-Miyaura cross-coupling reactions. For compounds synthesized using this reagent, typical binding assays may be performed. These involve incubating the test compound with purified enzymes or receptors in buffered solutions, with binding affinity measured by SPR, ITC, or fluorescence-based methods.
|
| Cell Assay |
Cell-based assays are not directly performed on 4-aminophenylboronic acid pinacol ester due to its lack of biological activity. However, drug candidates synthesized from this intermediate may be tested in cellular systems. Typical studies involve culturing cells in appropriate media, treating with the synthesized compound, and assessing cell viability, proliferation, and other endpoints over 24–72 hours.
|
| Animal Protocol |
In vivo animal studies are not conducted with 4-aminophenylboronic acid pinacol ester itself, as it is a chemical reagent. Drug candidates synthesized from this intermediate may be evaluated in animal models for efficacy, pharmacokinetics, and toxicity. Typical studies involve oral or intravenous administration to rodents, with monitoring of plasma drug levels, tissue distribution, and disease-relevant endpoints. All studies follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
4-Aminophenylboronic acid pinacol ester is a synthetic chemical reagent and is not subject to pharmacokinetic evaluation as a drug. Its physicochemical properties include a molecular weight of 219.09 g/mol and a molecular formula of C12H18BNO2. The compound is stable under normal storage conditions and is available in high purity (≥97–98%). The pinacol ester protecting group provides stability and allows for selective deprotection under mild conditions for further functionalization.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 4-aminophenylboronic acid pinacol ester has not been extensively characterized. As a boronic ester and aniline derivative, it may pose health hazards, including skin and eye irritation. Standard laboratory safety precautions should be observed, including the use of personal protective equipment (gloves, goggles, lab coat) and adequate ventilation. Ingestion or inhalation should be avoided.
|
| References |
[1]. Dai, Y., Hartandi, K., Ji, Z., et al al. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based ORALLY ACTIVE MULTITARGED Receptor Tyrosine Kinase Inchibitorj. Chem.50 (7) 1584-1597 (2007).
[2]. Paraiso, KHT, HAARBERG, He, Wood, E., ET Al.The HSP9 0 Inhibitor XL888 Overcomes Braf Inchibitor Resistance Mediated Through diverse mechanisms Clin. Cancer Res. 18(9) 2502-2514(2012). |
| Additional Infomation |
4-Aminophenylboronic acid pinacol ester is not a drug but a valuable chemical reagent and building block for organic synthesis. It is widely used in Suzuki-Miyaura cross-coupling reactions to construct biaryl structures found in many pharmaceuticals. The compound is also used for mercury(II) detection by fluorometry. It serves as a key intermediate in medicinal chemistry for the synthesis of drug candidates and bioactive molecules. It is not approved for clinical use.
|
| Molecular Formula |
C12H18BNO2
|
|---|---|
| Molecular Weight |
219.09
|
| Exact Mass |
219.143
|
| CAS # |
214360-73-3
|
| PubChem CID |
2734620
|
| Appearance |
Brown to gray solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
340.0±25.0 °C at 760 mmHg
|
| Melting Point |
165-169 °C(lit.)
|
| Flash Point |
159.4±23.2 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.517
|
| LogP |
2.149
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
16
|
| Complexity |
244
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1B(C2C([H])=C([H])C(=C([H])C=2[H])N([H])[H])OC(C([H])([H])[H])(C([H])([H])[H])C1(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
ZANPJXNYBVVNSD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H18BNO2/c1-11(2)12(3,4)16-13(15-11)9-5-7-10(14)8-6-9/h5-8H,14H2,1-4H3
|
| Chemical Name |
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (456.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5643 mL | 22.8217 mL | 45.6433 mL | |
| 5 mM | 0.9129 mL | 4.5643 mL | 9.1287 mL | |
| 10 mM | 0.4564 mL | 2.2822 mL | 4.5643 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
